Apyx Medical (NASDAQ:APYX) Announces Quarterly Earnings Results

Apyx Medical (NASDAQ:APYX) posted its earnings results on Tuesday. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03, FiscalAI reports. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%.The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $19.12 million.

Apyx Medical Price Performance

APYX stock opened at $3.43 on Tuesday. The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44. The firm has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.30. Apyx Medical has a 52-week low of $0.76 and a 52-week high of $4.50. The firm has a market capitalization of $131.16 million, a price-to-earnings ratio of -9.53 and a beta of 1.61.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in Apyx Medical in the third quarter worth $28,000. Osaic Holdings Inc. bought a new position in shares of Apyx Medical during the second quarter valued at $50,000. Franklin Resources Inc. purchased a new position in shares of Apyx Medical in the 3rd quarter worth about $59,000. Hudson Bay Capital Management LP bought a new position in Apyx Medical in the 4th quarter worth about $73,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Apyx Medical in the 4th quarter worth about $111,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on APYX shares. Roth Mkm began coverage on Apyx Medical in a research report on Monday, December 15th. They set a “buy” rating and a $6.00 price target on the stock. Citizens Jmp upgraded Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective for the company in a report on Wednesday, November 12th. Zacks Research raised Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.